Since alternative promoter start sites can have an effect on mRNA splicing, e.g. for the MAPT gene35—where alternative promoter usage leads to novel shorter transcripts in Alzheimer disease—we wanted to test if any of our selected sgRNAs targeting different transcriptional start sites would affect the downregulation or expression ratio of the different isoforms. Here, MAPT is linked to Alzheimer disease.